Market Capitalization

Pan-European exchange reports a strong start to 2026, fueled by a historic defense IPO and a dramatic spike in foreign exchange and metals trading.

Struggling garment and logistics firm Addentax Group announces a radical pivot, proposing to acquire an AI-powered crypto wealth platform in a bold move.

Amid Chapter 11 liquidation, LiDAR firm Luminar sells off key assets to pay creditors, offering to buy back senior notes at a premium.

Mawson Infrastructure reports a steep Q4 revenue drop but a smaller annual loss, clearing major legal hurdles to focus on its AI and green energy future.

Former Senator Joe Manchin and pharma exec Heather Manchin join BlinkRx, bringing political and industry muscle to the fight for affordable medicine.

Canadian biotech Satellos Bioscience seeks a Nasdaq listing and a $50M public offering to advance its promising muscle regeneration drug for Duchenne.

Tamarack Resort launches new multi-million dollar townhomes, marking a new chapter in Idaho's booming luxury mountain living and resort development.

A health-tech firm with a mission for free care and a $1.3B valuation eyes a Nasdaq listing, but its revenue-free history raises critical questions.

Everbright Digital hopes a 1-for-16 reverse stock split will save its Nasdaq listing, but the move raises questions about its metaverse-focused future.

With major drug approvals on the horizon, Nuvalent's leadership will detail its strategy for its next-gen cancer therapies at an influential investor summit.

Volvo Cars' Q4 profits fell, but a tough cost-cutting plan boosted cash flow, setting the stage for its critical electric vehicle push in a tough market.

The semiconductor giant posted a huge Non-GAAP profit but a stunning IFRS loss for 2025. What's behind the numbers and why are investors cheering?

Sila Realty Trust sets its 2025 earnings date. Investors are watching to see if its strategic acquisitions and dividend policy signal strength for the sector.

In a surprise move, Sun Communities' new CFO is out after less than 30 days. His predecessor steps back in, aiming to calm markets amid a search.

With its lead drug MOLBREEVI under FDA review, Savara's upcoming investor talks are a critical test of its path from clinical trials to market.

As AI's power needs skyrocket, GridAI brings in veteran Tim Healy to lead its charge. Can his software-first approach solve the grid's biggest challenge?

Automotive seating giant Adient boosts its 2026 forecast, banking on strong North American production and operational gains, despite a reported net loss.

With promising new pipeline data and a major earnings report looming, Aclaris Therapeutics heads to two investor summits, placing its strategy on display.

As Telix prepares its 2025 financials, all eyes are on its blockbuster revenue, pipeline progress, and its leading role in the booming radiopharma sector.

The iconic basketball-playing dog is back! Cineverse and Air Bud Entertainment are betting on nostalgia and a new story to relaunch a beloved franchise.